Matthew P Giannetti1, Emily Weller2, Concetta Bormans3, Peter Novak4, Matthew J Hamilton5, Mariana Castells6. 1. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: mgiannetti@bwh.harvard.edu. 2. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts. 3. Gene by Gene, Ltd, Houston, Texas. 4. Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts. 5. Harvard Medical School, Boston, Massachusetts; Division of Gastroenterology, Endoscopy, and Hepatology, Brigham and Women's Hospital, Boston, Massachusetts. 6. Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Hereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic trait characterized by multiple copies of the alpha-tryptase gene at the TPSAB1 locus. Previously described symptomatology involves multiple organ systems and anaphylaxis. The spectrum of mast cell activation symptoms is unknown, as is its association with specific genotypes. OBJECTIVE: To describe clinical, laboratory, and genetic characteristics of patients referred for the evaluation of mast cell activation-related symptoms and genotype-confirmed HαT. METHODS: We retrospectively describe clinical characteristics, baseline tryptase, and tryptase genotype in 101 patients. Patients were referred for mast cell activation-related symptoms and underwent genotyping to confirm diagnosis of HαT. RESULTS: Of 101 patients, 80% were female with average tryptase of 17.2 ng/mL. Tryptase was less than 11.4 ng/mL in 8.9% and greater than 20 ng/mL in 22.3% (range 6.2-51.3 ng/mL). KIT D816V mutation was negative in all subjects tested. 2α:3β was the most common genotype but did not correlate with tryptase levels. Unprovoked anaphylaxis was noted in 57% of the subjects with heterogeneous genotypes. Most common symptoms include gastrointestinal, cutaneous, psychiatric, pulmonary, cardiovascular, and neurologic. A total of 85% of patients were taking H1- or H2-antihistamines with partial symptom relief. Omalizumab was effective at suppressing anaphylaxis or urticaria in 94% of the patients. CONCLUSION: HαT encompasses a broad range of baseline tryptase and should be considered in patients with symptoms of mast cell activation and tryptase levels greater than 6.2 ng/mL. Patients may present with complex symptomatology including cutaneous, gastrointestinal, neurologic, and psychiatric symptoms and anaphylaxis, some of which respond to omalizumab.
BACKGROUND:Hereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic trait characterized by multiple copies of the alpha-tryptase gene at the TPSAB1 locus. Previously described symptomatology involves multiple organ systems and anaphylaxis. The spectrum of mast cell activation symptoms is unknown, as is its association with specific genotypes. OBJECTIVE: To describe clinical, laboratory, and genetic characteristics of patients referred for the evaluation of mast cell activation-related symptoms and genotype-confirmed HαT. METHODS: We retrospectively describe clinical characteristics, baseline tryptase, and tryptase genotype in 101 patients. Patients were referred for mast cell activation-related symptoms and underwent genotyping to confirm diagnosis of HαT. RESULTS: Of 101 patients, 80% were female with average tryptase of 17.2 ng/mL. Tryptase was less than 11.4 ng/mL in 8.9% and greater than 20 ng/mL in 22.3% (range 6.2-51.3 ng/mL). KITD816V mutation was negative in all subjects tested. 2α:3β was the most common genotype but did not correlate with tryptase levels. Unprovoked anaphylaxis was noted in 57% of the subjects with heterogeneous genotypes. Most common symptoms include gastrointestinal, cutaneous, psychiatric, pulmonary, cardiovascular, and neurologic. A total of 85% of patients were taking H1- or H2-antihistamines with partial symptom relief. Omalizumab was effective at suppressing anaphylaxis or urticaria in 94% of the patients. CONCLUSION: HαT encompasses a broad range of baseline tryptase and should be considered in patients with symptoms of mast cell activation and tryptase levels greater than 6.2 ng/mL. Patients may present with complex symptomatology including cutaneous, gastrointestinal, neurologic, and psychiatric symptoms and anaphylaxis, some of which respond to omalizumab.
Authors: Sarah C Glover; Melody C Carter; Peter Korošec; Patrizia Bonadonna; Lawrence B Schwartz; Joshua D Milner; George H Caughey; Dean D Metcalfe; Jonathan J Lyons Journal: Ann Allergy Asthma Immunol Date: 2021-08-13 Impact factor: 6.248
Authors: Aubri M Waters; Hyun J Park; Andrew L Weskamp; Allyson Mateja; Megan E Kachur; Jonathan J Lyons; Benjamin J Rosen; Nathan A Boggs Journal: J Allergy Clin Immunol Pract Date: 2022-01-12
Authors: Allyson Mateja; Qinlu Wang; Jack Chovanec; Jiwon Kim; Kenneth J Wilson; Lawrence B Schwartz; Sarah C Glover; Melody C Carter; Dean D Metcalfe; Erica Brittain; Jonathan J Lyons Journal: J Allergy Clin Immunol Date: 2021-08-20 Impact factor: 14.290
Authors: Maribel Vazquez; Jack Chovanec; Jiwon Kim; Thomas DiMaggio; Joshua D Milner; Clair A Francomano; Christina A Gurnett; Marco Ritelli; Marina Colombi; Jonathan J Lyons Journal: HGG Adv Date: 2022-02-22
Authors: Merel C Onnes; Abdulrazzaq Alheraky; Martijn C Nawijn; Tim E Sluijter; André B Mulder; Suzanne Arends; Hanneke N G Oude Elberink Journal: Clin Transl Allergy Date: 2022-09-07 Impact factor: 5.657